Clinical trial
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney…
NCT00408902 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00408902 |
|---|---|
| Title | Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer |
| Official title | Phase II Study of MLN518 in Patients With Metastatic Clear Cell Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug, Other |
| Interventions | tandutinib, laboratory biomarker analysis |
| Enrollment | 10 |
| Start date | Nov 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Dec 7, 2006 |
| Last update posted | Nov 22, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: